Skip to main content

Advertisement

SpringerLink
Log in

Homing of Cancer Cells to the Bone

  • Original Paper
  • Published:
Cancer Microenvironment

Abstract

A variety of tumor cells preferentially home to the bone. The homing of cancer cells to the bone represents a multi-step process that involves malignant progression of the tumor, invasion of the tumor through the extracellular matrix and the blood vessels and settling of the tumor cells in the bone. Gaining a greater understanding as to the mechanisms used by cancer cells in these processes will facilitate the design of drugs which could specifically target the homing process. In this review we will discuss the properties of tumor cells and the bone microenvironment which promote homing of a cancer cell to the bone. We will highlight the different steps and the molecular pathways involved when a cancer cell metastasize to the bone. Since bone is the major home for hematopoietic stem cells (HSCs), we will also highlight the similarities between the homing of cancer and HSC to the bone. Finally we will conclude with therapeutic and early detection strategies which can prevent homing of a cancer cell to the bone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s

    PubMed  Google Scholar 

  2. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593

    PubMed  CAS  Google Scholar 

  3. Jemal A et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66

    PubMed  Google Scholar 

  4. Mantyh PW et al (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2(3):201–209

    PubMed  CAS  Google Scholar 

  5. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594

    PubMed  CAS  Google Scholar 

  6. Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5(16):1744–1750

    PubMed  CAS  Google Scholar 

  7. Morgan TM et al (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15(2):677–683

    PubMed  CAS  Google Scholar 

  8. Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802

    PubMed  CAS  Google Scholar 

  9. Cristofanilli M et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

    PubMed  CAS  Google Scholar 

  10. Pierga JY et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14(21):7004–7010

    PubMed  CAS  Google Scholar 

  11. Roudier M (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34(7):646–653

    PubMed  Google Scholar 

  12. Liu W et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15(5):559–565

    PubMed  CAS  Google Scholar 

  13. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655–1664

    PubMed  CAS  Google Scholar 

  14. Guise TA et al (2006) Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases. Clin Cancer Res 12(20):6213s–6216s

    PubMed  CAS  Google Scholar 

  15. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428

    PubMed  CAS  Google Scholar 

  16. Vicovac L, Aplin JD (1996) Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat (Basel) 156(3):202–216

    CAS  Google Scholar 

  17. Zeisberg EM et al (2007) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13(8):952–961

    PubMed  CAS  Google Scholar 

  18. Zeisberg M et al (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282(32):23337–23347

    PubMed  CAS  Google Scholar 

  19. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454

    PubMed  CAS  Google Scholar 

  20. Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715

    PubMed  CAS  Google Scholar 

  21. Morel AP et al (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3(8):e2888

    PubMed  Google Scholar 

  22. Lapidot T et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648

    PubMed  CAS  Google Scholar 

  23. Al-Hajj M et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988

    PubMed  CAS  Google Scholar 

  24. Ginestier C et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567

    PubMed  CAS  Google Scholar 

  25. Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828

    PubMed  CAS  Google Scholar 

  26. Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76(1):69–125

    PubMed  CAS  Google Scholar 

  27. Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506–520

    PubMed  CAS  Google Scholar 

  28. Kuperwasser C et al (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101(14):4966–4971

    PubMed  CAS  Google Scholar 

  29. Orimo A et al (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335–348

    PubMed  CAS  Google Scholar 

  30. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573

    PubMed  CAS  Google Scholar 

  31. Sternlicht MD et al (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98(2):137–146

    PubMed  CAS  Google Scholar 

  32. Karnoub AE et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557–563

    PubMed  CAS  Google Scholar 

  33. Goldstein RH et al (2010) Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 70(24):10044–10050

    PubMed  CAS  Google Scholar 

  34. Subarsky P, Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20(3):237–250

    PubMed  CAS  Google Scholar 

  35. John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7(1):14–23

    PubMed  CAS  Google Scholar 

  36. Wilson TJ, Singh RK (2008) Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta 1785(2):85–95

    PubMed  CAS  Google Scholar 

  37. Bachmeier BE et al (2001) Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 21(6A):3821–3828

    PubMed  CAS  Google Scholar 

  38. Nakopoulou L et al (2003) MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 77(2):145–155

    PubMed  CAS  Google Scholar 

  39. Eck SM et al (2009) Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116(1):79–90

    PubMed  CAS  Google Scholar 

  40. Klein A et al (2009) Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 276(2):212–220

    PubMed  CAS  Google Scholar 

  41. Dong Z et al (2005) Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166(4):1173–1186

    PubMed  CAS  Google Scholar 

  42. Nabha SM et al (2008) Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner. Int J Cancer 122(11):2482–2490

    PubMed  CAS  Google Scholar 

  43. Janowska-Wieczorek A et al (2000) Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol 28(11):1274–1285

    PubMed  CAS  Google Scholar 

  44. Sloane BF (1990) Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1(2):137–152

    PubMed  CAS  Google Scholar 

  45. Sinha AA et al (2001) Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 48(4):274–284

    PubMed  CAS  Google Scholar 

  46. Brubaker KD et al (2003) Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18(2):222–230

    PubMed  CAS  Google Scholar 

  47. Testa JE, Quigley JP (1990) The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 9(4):353–367

    PubMed  CAS  Google Scholar 

  48. Achbarou A et al (1994) Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54(9):2372–2377

    PubMed  CAS  Google Scholar 

  49. Rabbani SA et al (1990) An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-such as cells. Biochem Biophys Res Commun 173(3):1058–1064

    PubMed  CAS  Google Scholar 

  50. Christopherson KW 2nd, Hangoc G, Broxmeyer HE (2002) Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol 169(12):7000–7008

    PubMed  CAS  Google Scholar 

  51. Sun YX et al (2008) CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis 25(7):765–776

    PubMed  CAS  Google Scholar 

  52. Christopherson KW 2nd et al (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305(5686):1000–1003

    PubMed  CAS  Google Scholar 

  53. Cramer SD, Chen Z, Peehl DM (1996) Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-such as domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156(2 Pt 1):526–531

    PubMed  CAS  Google Scholar 

  54. Dallas SL et al (1995) Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131(2):539–549

    PubMed  CAS  Google Scholar 

  55. Iwamura M et al (1996) Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48(2):317–325

    PubMed  CAS  Google Scholar 

  56. Killian CS et al (1993) Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192(2):940–947

    PubMed  CAS  Google Scholar 

  57. Nadiminty N et al (2006) Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 12(5):1420–1430

    PubMed  CAS  Google Scholar 

  58. Nagasawa T, Tachibana K, Kishimoto T (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 10(3):179–185

    PubMed  CAS  Google Scholar 

  59. Ponomaryov T et al (2000) Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106(11):1331–1339

    PubMed  CAS  Google Scholar 

  60. Loetscher M et al (1994) Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 269(1):232–237

    PubMed  CAS  Google Scholar 

  61. Peled A et al (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283(5403):845–848

    PubMed  CAS  Google Scholar 

  62. Kollet O et al (2001) Rapid and efficient homing of human CD34(+)CD38(−/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice. Blood 97(10):3283–3291

    PubMed  CAS  Google Scholar 

  63. Peled A et al (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 104(9):1199–1211

    PubMed  CAS  Google Scholar 

  64. Peled A et al (2000) The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95(11):3289–3296

    PubMed  CAS  Google Scholar 

  65. Wysoczynski M et al (2005) Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 105(1):40–48

    PubMed  CAS  Google Scholar 

  66. Taichman RS et al (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62(6):1832–1837

    PubMed  CAS  Google Scholar 

  67. Sun YX et al (2005) Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20(2):318–329

    PubMed  CAS  Google Scholar 

  68. Sun YX et al (2003) Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89(3):462–473

    PubMed  CAS  Google Scholar 

  69. Arya M et al (2004) The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4(4):291–303

    PubMed  CAS  Google Scholar 

  70. Wang J et al (2008) The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 283(7):4283–4294

    PubMed  CAS  Google Scholar 

  71. Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56

    PubMed  CAS  Google Scholar 

  72. Sloan EK, Anderson RL (2002) Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 59(9):1491–1502

    PubMed  CAS  Google Scholar 

  73. Kang Y et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549

    PubMed  CAS  Google Scholar 

  74. Luker KE, Luker GD (2006) Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 238(1):30–41

    PubMed  CAS  Google Scholar 

  75. Shim H et al (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346(1):252–258

    PubMed  CAS  Google Scholar 

  76. Salvucci O et al (2006) The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97(3):275–283

    PubMed  CAS  Google Scholar 

  77. Bradstock KF et al (2000) Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia 14(5):882–888

    PubMed  CAS  Google Scholar 

  78. Bendall LJ et al (2005) Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res 65(8):3290–3298

    PubMed  CAS  Google Scholar 

  79. Spiegel A et al (2004) Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 103(8):2900–2907

    PubMed  CAS  Google Scholar 

  80. Mohle R et al (1998) The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91(12):4523–4530

    PubMed  CAS  Google Scholar 

  81. Voermans C et al (2002) Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 16(4):650–657

    PubMed  CAS  Google Scholar 

  82. Burger JA et al (2003) CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol 122(4):579–589

    PubMed  CAS  Google Scholar 

  83. Tavor S et al (2004) CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64(8):2817–2824

    PubMed  CAS  Google Scholar 

  84. Monaco G et al (2004) Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 22(2):188–201

    PubMed  Google Scholar 

  85. Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94(11):3658–3667

    PubMed  CAS  Google Scholar 

  86. Burger M et al (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106(5):1824–1830

    PubMed  CAS  Google Scholar 

  87. Lu Y et al (2008) CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res 6(4):546–554

    PubMed  CAS  Google Scholar 

  88. Takahashi S et al (1994) Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J Biol Chem 269(46):28696–28701

    PubMed  CAS  Google Scholar 

  89. Jung Y et al (2007) Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 110(1):82–90

    PubMed  CAS  Google Scholar 

  90. Cole SP et al (1992) Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 65(4):498–502

    PubMed  CAS  Google Scholar 

  91. Emoto K et al (2001) Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92(6):1419–1426

    PubMed  CAS  Google Scholar 

  92. Roseman BJ et al (1994) Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6(12):561–567

    PubMed  CAS  Google Scholar 

  93. Vishwanatha JK et al (1993) Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14(12):2575–2579

    PubMed  CAS  Google Scholar 

  94. Shiozawa Y et al (2008) Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 105(2):370–380

    PubMed  CAS  Google Scholar 

  95. Shiozawa Y, Pedersen EA, Taichman RS (2010) GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp Hematol 38(2):132–140

    PubMed  CAS  Google Scholar 

  96. Gjerdrum C et al (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107(3):1124–1129

    PubMed  CAS  Google Scholar 

  97. Koorstra JB et al (2009) The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8(7):618–626

    PubMed  CAS  Google Scholar 

  98. Rankin EB et al (2010) AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70(19):7570–7579

    PubMed  CAS  Google Scholar 

  99. Hector A et al (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10(10):1009–1018

    PubMed  Google Scholar 

  100. Gustafsson A et al (2009) Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One 4(10):e7575

    PubMed  Google Scholar 

  101. Shiozawa Y et al (2010) GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12(2):116–127

    PubMed  CAS  Google Scholar 

  102. Hill A et al (2006) The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett 237(1):1–9

    PubMed  CAS  Google Scholar 

  103. Avigdor A et al (2004) CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103(8):2981–2989

    PubMed  CAS  Google Scholar 

  104. Nilsson SK et al (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106(4):1232–1239

    PubMed  CAS  Google Scholar 

  105. Fedarko NS et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7(12):4060–4066

    PubMed  CAS  Google Scholar 

  106. Rudland PS et al (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–3427

    PubMed  CAS  Google Scholar 

  107. Thalmann GN et al (1999) Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 5(8):2271–2277

    PubMed  CAS  Google Scholar 

  108. Tuck AB et al (1997) Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121(6):578–584

    PubMed  CAS  Google Scholar 

  109. Tuck AB et al (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18(29):4237–4246

    PubMed  CAS  Google Scholar 

  110. Wai PY, Kuo PC (2004) The role of Osteopontin in tumor metastasis. J Surg Res 121(2):228–241

    PubMed  CAS  Google Scholar 

  111. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285(5430):1028–1032

    PubMed  CAS  Google Scholar 

  112. Furger KA et al (2003) Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1(11):810–819

    PubMed  CAS  Google Scholar 

  113. Sun YX et al (2007) Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67(1):61–73

    PubMed  CAS  Google Scholar 

  114. Sethi T et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5(6):662–668

    PubMed  CAS  Google Scholar 

  115. Hodkinson PS et al (2006) ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 13(10):1776–1788

    PubMed  CAS  Google Scholar 

  116. Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20(36):4995–5004

    PubMed  CAS  Google Scholar 

  117. Matsunaga T et al (2003) Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9(9):1158–1165

    PubMed  CAS  Google Scholar 

  118. Verfaillie CM (1998) Adhesion receptors as regulators of the hematopoietic process. Blood 92(8):2609–2612

    PubMed  CAS  Google Scholar 

  119. Taichman RS (2005) Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105(7):2631–2639

    PubMed  CAS  Google Scholar 

  120. Chu K et al (2008) Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6(8):1259–1267

    PubMed  CAS  Google Scholar 

  121. Huang CF et al (2010) Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res 70(11):4580–4589

    PubMed  CAS  Google Scholar 

  122. Tamura D et al (2008) Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol 33(1):17–24

    PubMed  CAS  Google Scholar 

  123. Wein F et al (2010) N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res 4(2):129–139

    PubMed  CAS  Google Scholar 

  124. Kiel MJ et al (2009) Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell 4(2):170–179

    PubMed  CAS  Google Scholar 

  125. Fidler IJ, Kim S-J, Langley RR (2007) The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 101(4):927–936

    PubMed  CAS  Google Scholar 

  126. Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328(3):679–687

    PubMed  CAS  Google Scholar 

  127. Lacey DL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165–176

    PubMed  CAS  Google Scholar 

  128. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337–342

    PubMed  CAS  Google Scholar 

  129. Simonet WS et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319

    PubMed  CAS  Google Scholar 

  130. Grimaud E et al (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163(5):2021–2031

    PubMed  CAS  Google Scholar 

  131. Brown JM et al (2001) Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57(4):611–616

    PubMed  CAS  Google Scholar 

  132. Lynch CC et al (2005) MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7(5):485–496

    PubMed  CAS  Google Scholar 

  133. Sordillo EM, Pearse RN (2003) RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 97(3 Suppl):802–812

    PubMed  Google Scholar 

  134. Jones DH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692–696

    PubMed  CAS  Google Scholar 

  135. Miller J et al (2002) The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat Genet 32(4):645–649

    PubMed  CAS  Google Scholar 

  136. Komori T et al (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89(5):755–764

    PubMed  CAS  Google Scholar 

  137. Barnes GL et al (2003) Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63(10):2631–2637

    PubMed  CAS  Google Scholar 

  138. Enomoto H et al (2003) Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. J Biol Chem 278(26):23971–23977

    PubMed  CAS  Google Scholar 

  139. Pratap J et al (2005) The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25(19):8581–8591

    PubMed  CAS  Google Scholar 

  140. Pratap J et al (2006) Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25(4):589–600

    PubMed  CAS  Google Scholar 

  141. Akech J et al (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29(6):811–821

    PubMed  CAS  Google Scholar 

  142. Baniwal SK et al (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9:258

    PubMed  Google Scholar 

  143. Elliott RL, Blobe GC (2005) Role of transforming growth factor Beta in human cancer. J Clin Oncol 23(9):2078–2093

    PubMed  CAS  Google Scholar 

  144. Mohammad KS et al (2009) Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 4(4):e5275

    PubMed  Google Scholar 

  145. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958):577–584

    PubMed  CAS  Google Scholar 

  146. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1(3):169–178

    PubMed  CAS  Google Scholar 

  147. Dallas SL et al (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277(24):21352–21360

    PubMed  CAS  Google Scholar 

  148. Kakonen SM et al (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277(27):24571–24578

    PubMed  CAS  Google Scholar 

  149. Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228–236

    PubMed  CAS  Google Scholar 

  150. Kondo H, Guo J, Bringhurst FR (2002) Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J Bone Miner Res 17(9):1667–1679

    PubMed  CAS  Google Scholar 

  151. Gallwitz WE, Guise TA, Mundy GR (2002) Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 110(10):1559–1572

    PubMed  CAS  Google Scholar 

  152. Javelaud D et al (2007) Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67(5):2317–2324

    PubMed  CAS  Google Scholar 

  153. Alexaki VI et al (2010) GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst 102(15):1148–1159

    PubMed  CAS  Google Scholar 

  154. Gazzerro E, Canalis E (2006) Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7(1–2):51–65

    PubMed  CAS  Google Scholar 

  155. Katsuno Y et al (2008) Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27(49):6322–6333

    PubMed  CAS  Google Scholar 

  156. Lai TH et al (2008) Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 68(12):1341–1353

    PubMed  CAS  Google Scholar 

  157. Virk MS et al (2009) Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 44(1):160–167

    PubMed  CAS  Google Scholar 

  158. Hauschka PV et al (1986) Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261(27):12665–12674

    PubMed  CAS  Google Scholar 

  159. Goya M et al (2004) Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-such as growth factors. Cancer Res 64(17):6252–6258

    PubMed  CAS  Google Scholar 

  160. van Golen CM et al (2006) Insulin-such as growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res 66(13):6570–6578

    PubMed  Google Scholar 

  161. Kingsley LA et al (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609–2617

    PubMed  CAS  Google Scholar 

  162. Zhong H et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59(22):5830–5835

    PubMed  CAS  Google Scholar 

  163. Le QT, Denko NC, Giaccia AJ (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23(3–4):293–310

    PubMed  CAS  Google Scholar 

  164. Garayoa M et al (2000) Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14(6):848–862

    PubMed  CAS  Google Scholar 

  165. McMahon S et al (2006) Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 281(34):24171–24181

    PubMed  CAS  Google Scholar 

  166. Hiraga T et al (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67(9):4157–4163

    PubMed  CAS  Google Scholar 

  167. Brandao-Burch A et al (2005) Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int 77(3):167–174

    PubMed  CAS  Google Scholar 

  168. Webb SD, Sherratt JA, Fish RG (1999) Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model. Clin Exp Metastasis 17(5):397–407

    PubMed  CAS  Google Scholar 

  169. Shannon AM et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29(4):297–307

    PubMed  CAS  Google Scholar 

  170. Berger CE et al (2001) Scanning electrochemical microscopy at the surface of bone-resorbing osteoclasts: evidence for steady-state disposal and intracellular functional compartmentalization of calcium. J Bone Miner Res 16(11):2092–2102

    PubMed  CAS  Google Scholar 

  171. Chattopadhyay N (2006) Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy. Am J Physiol Endocrinol Metab 290(5):E761–E770

    PubMed  CAS  Google Scholar 

  172. Sanders JL et al (2000) Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141(12):4357–4364

    PubMed  CAS  Google Scholar 

  173. Sanders JL et al (2001) Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab 281(6):E1267–E1274

    PubMed  CAS  Google Scholar 

  174. Liao J et al (2006) Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 66(18):9065–9073

    PubMed  CAS  Google Scholar 

  175. Mihai R et al (2006) Expression of the calcium receptor in human breast cancer–a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 32(5):511–515

    PubMed  CAS  Google Scholar 

  176. Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6(2):93–106

    PubMed  CAS  Google Scholar 

  177. Yin T, Li L (2006) The stem cell niches in bone. J Clin Invest 116(5):1195–1201

    PubMed  CAS  Google Scholar 

  178. Shiozawa Y, et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298–1312

    Google Scholar 

  179. Kaplan RN et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438(7069):820–827

    PubMed  CAS  Google Scholar 

  180. Roelofs AJ et al (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12(20 Pt 2):6222s–6230s

    PubMed  CAS  Google Scholar 

  181. Fizazi K et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27(10):1564–1571

    PubMed  CAS  Google Scholar 

  182. Mohammad KS et al (2011) TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 71(1):175–184

    PubMed  CAS  Google Scholar 

  183. Buijs JT et al (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171(3):1047–1057

    PubMed  CAS  Google Scholar 

  184. Coenegrachts L et al (2010) Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 70(16):6537–6547

    PubMed  CAS  Google Scholar 

  185. Carducci MA, Jimeno A (2006) Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12(20 Pt 2):6296s–6300s

    PubMed  CAS  Google Scholar 

  186. Zhao Y et al (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67(12):5821–5830

    PubMed  CAS  Google Scholar 

  187. Mori Y et al (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104(7):2149–2154

    PubMed  CAS  Google Scholar 

  188. Petit I et al (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3(7):687–694

    PubMed  CAS  Google Scholar 

  189. Lapidot T, Dar A, Kollet O (2005) How do stem cells find their way home? Blood 106(6):1901–1910

    PubMed  CAS  Google Scholar 

  190. Abkowitz JL et al (2003) Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102(4):1249–1253

    PubMed  CAS  Google Scholar 

  191. Azab AK et al (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113(18):4341–4351

    PubMed  CAS  Google Scholar 

  192. Nervi B et al (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113(24):6206–6214

    PubMed  CAS  Google Scholar 

  193. Burger JA, Stewart DJ (2009) CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs 18(4):481–490

    PubMed  CAS  Google Scholar 

  194. Hastie C et al (2008) Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem 283(18):12595–12603

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. Laurie K. McCauley and Evan T. Keller for scientific discussions. This work is directly supported by a Pediatric Oncology Research Fellowship (Y.S.). The National Cancer Institute (CA093900, K.J.P. and R.S.T., CA141426, R.S.T.), the Department of Defense (Y.S., K.J.P. and R.S.T) and the Prostate Cancer Foundation (K.J.P. and R.S.T.). K.J.P. receives support as an American Cancer Society Clinical Research Professor, NIH SPORE in prostate cancer grant P50 CA69568, and the Cancer Center support grant P30 CA46592.

Author information

Authors and Affiliations

  1. Department of Biologics and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, MI, 48109, USA

    Anjali Mishra

  2. Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, 48109, USA

    Yusuke Shiozawa & Russell S. Taichman

  3. Departments of Urology and Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 48109, USA

    Kenneth J. Pienta

  4. University of Michigan Dental School, 1011 North University Ave., Ann Arbor, MI, 48109, USA

    Russell S. Taichman

Authors
  1. Anjali Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yusuke Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth J. Pienta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Russell S. Taichman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell S. Taichman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mishra, A., Shiozawa, Y., Pienta, K.J. et al. Homing of Cancer Cells to the Bone. Cancer Microenvironment 4, 221–235 (2011). https://doi.org/10.1007/s12307-011-0083-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12307-011-0083-6

Keywords

Search

Navigation